Shared on11 Sep 25Fair value Decreased 39%
Despite a substantial increase in consensus revenue growth forecasts, ANGLE’s future P/E multiple has halved, reflecting a notable de-rating and driving the fair value estimate down from £0.28 to £0.17. What's in the News ANGLE plc announced a collaboration with Myriad Genetics, utilising ANGLE's Parsortix system to process cancer patient blood samples for molecular analysis, comparing CTC-DNA with matched tissue samples via Myriad's assay; further details remain confidential.